DOCSLIB.ORG

Rare Variants in the Complement Factor H–Related Protein 5 Gene Contribute to Genetic Susceptibility to Iga Nephropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rare Variants in the Complement Factor H–Related Protein 5 Gene Contribute to Genetic Susceptibility to Iga Nephropathy CLINICAL RESEARCH www.jasn.org Rare Variants in the Complement Factor H–Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy †‡ †‡ †‡ †‡ †‡ Ya-Ling Zhai,* § Si-Jun Meng,* § Li Zhu,* § Su-Fang Shi,* § Su-Xia Wang,* § †‡ †‡ †‡ †‡ †‡ Li-Jun Liu,* § Ji-Cheng Lv,* § Feng Yu,* § Ming-Hui Zhao,* § and Hong Zhang* § *Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; †Institute of Nephrology, Peking University, Beijing, China; ‡Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China; and §Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China ABSTRACT A recent genome–wide association study of IgA nephropathy (IgAN) identified 1q32, which contains multiple complement regulatory genes, including the complement factor H (CFH) gene and the comple- ment factor H–related (CFHRs) genes, as an IgAN susceptibility locus. Abnormal complement activation caused by a mutation in CFHR5 was shown to cause CFHR5 nephropathy, which shares many character- istics with IgAN. To explore the genetic effect of variants in CFHR5 on IgAN susceptibility, we recruited 500 patients with IgAN and 576 healthy controls for genetic analysis. We sequenced all exons and their intronic flanking regions as well as the untranslated regions of CFHR5 and compared the frequencies of identified variants using the sequence kernel association test. We identified 32 variants in CFHR5, includ- ing 28 rare and four common variants. The distribution of rare variants in CFHR5 in patients with IgAN differed significantly from that in controls (P=0.002). Among the rare variants, in silico programs predicted nine as potential functional variants, which we then assessed in functional assays. Compared with wild-type CFHR5, three recombinant CFHR5 proteins, CFHR5-M (c.508G.A/p.Val170Met), CFHR5-S (c.533A.G/p. Asn178Ser), and CFHR5-D (c.822A.T/p.Glu274Asp), showed significantly higher C3b binding capacity (CFHR5-M: 109.67%63.54%; P=0.02; CFHR5-S: 174.27%69.78%; P,0.001; CFHR5-D: 127.25%61.75%; P,0.001), whereas another recombinant CFHR5 (c.776T.A/p.Leu259Termination) showed less C3b bind- ing (56.89%60.57%; P,0.001). Our study found that rare variants in CFHR5 may contribute to the genetic susceptibility to IgAN, which suggests that CFHR5 is an IgAN susceptibility gene. J Am Soc Nephrol 27: 2894–2905, 2016. doi: 10.1681/ASN.2015010012 IgA nephropathy (IgAN) is the most common pri- IgAN. A recent genome–wide association study mary GN worldwide.1 Recently, important discov- (GWAS)7 and a GWAS replication study8 identified eries have been made regarding the pathogenesis of and confirmed 1q32 as an IgAN susceptibility IgAN,2–5 such as the aberrant glycosylation of IgA1 and the presence of antiglycan antibodies in circu- lation as well as the role of transferrin receptors in Received January 5, 2015. Accepted December 20, 2015. glomeruli. However, there are still many unknown Y.-L.Z. and S.-J.M. contributed equally to this work. aspects in IgAN. Although complement activation Published online ahead of print. Publication date available at has been widely accepted for a long time to occur in www.jasn.org. IgAN,6 the exact pathways and regulatory mecha- Correspondence: Dr. Li Zhu, Renal Division, Department of nisms are still unclear. Medicine, Peking University First Hospital, Peking University In- Meanwhile, from racial and ethnic variations in stitute of Nephrology, Beijing 100034, China. Email: funnyzhuli@ disease incidence to familial aggregation of IgAN, bjmu.edu.cn increasing evidence implied a genetic effect on Copyright © 2016 by the American Society of Nephrology 2894 ISSN : 1046-6673/2709-2894 JAmSocNephrol27: 2894–2905, 2016 www.jasn.org CLINICAL RESEARCH locus, which suggested the involvement of genetic abnormal- Their proteinuria and eGFR levels were 1.42 (0.81–2.66) g/d ities in the complement factor H (CFH)and/orthecomplement and 84.19627.03 ml/min per 1.73 m2, respectively. In total, factor H–related (CFHRs) genes in IgAN. This region contains 13.60% (68 of 500) had hypertension. Regarding pathologic several complement regulatory genes, CFH-CFHRs. CFHRs, features, 47.60% of patients with IgAN had a strong intensity which include CFHR3, CFHR1, CFHR4, CFHR2,andCFHR5, of C3 deposition (3+ or 4+). Haas 1–5 were found in 8.60%, share high sequence homology with CFH. Accordingly, they 0.80%, 45.20%, 33.20%, and 12.20% of patients, respectively. have similar structures, which are built on a motif of distinct All patients were regularly followed for at least 1 year, with a functional domains called short consensus repeats (SCRs), mean follow-up time of 56.26 months. Patients’ treatment and and similar functions in complement regulation,9 although follow-up were conducted at an IgAN-specific clinic in Peking their precise biologic roles are not completely identical. University First Hospital and consistent with the Kidney Recently, a novel disease named CFHR5 nephropathy was Disease Improving Global Outcomes guideline.14 During identified after genetic analysis of a pedigree of Cypriot ances- follow-up, 16.80% (84 patients) of these patients reached a try with primary GN.10 Patients with CFHR5 nephropathy composited end point (ESRD, 50% eGFR decline, or death). presented with many characteristics, including young age The clinical, laboratory, and pathologic characteristics of the onset, tendency in men, repeated episodes of synpharyngitic recruited patients were similar to those of previously reported hematuria, mesangial matrix expansion, increased glomerular IgAN cohorts.15 cellularity, glomerular staining for C3, mesangial electron– dense deposits, and high recurrence rate after renal transplan- Identification of Genetic Variants in CFHR5 tation, which shared many similarities with IgAN.11 Patients All exons in the CFHR5 gene were amplified and screened for with CFHR5 nephropathy bear the same heterozygous inter- genetic variants in recruited individuals. In total, 32 variants nal duplication of the CFHR5 gene, which is likely to be the were identified (Figure 1, Table 1), including 10 in exons, 18 in cause of their glomerular lesions. introns, two in promoter, and two in 39 untranslated region The CFHR5 gene is located at 1q31.3 and spans 42 kb of the (UTR). Of 10 exonic variants, eight were nonsynonymous human genome. Its encoded product is a 62-kD protein coding (including one nonsynonymous stop gain and nonsy- named CFHR5. The CFHR5 gene has 10 exons encoded in nonymous stop loss), and two were synonymous changes. nine SCRs, in which SCR3–7andSCR8–9 showed a high ho- Among 32 variants, 16 were found in the dbSNP database, mology with SCR10–14 and SCR19–20 in CFH, respectively. whereas the other 16 variants were novel. CFHR5 is the most recently discovered CFHR protein, and it is also the one that showed the most similarity with CFH among Genetic Association Analyses of CFHR5 with IgAN the five CFHRs.12 As with CFH and other CFHRs, CFHR5 is Among the identified 32 variants, four were common variants produced in the liver, circulates in plasma, and functions as a (c.58+17T.A, c.431–80G.A, c.434G.A, and c.1147+24T. complement regulatory protein. Until today, the precise G; minor allele frequency [MAF] .0.01 in controls), whereas mechanism for CFHR5 in complement regulation is still un- the other 28 were rare. We only observed individuals with known.13 homozygous minor alleles in two common variants (c.58+ However, with respect to IgAN, the disease presents 17T.A and c.1147+24T.G) and not in the other two com- complement activation in glomeruli and has clinical features mon variants (c.431–80G.A [MAF=0.013] and c.434G.A similar to CFHR5 nephropathy, but whether some patients [MAF=0.013]) and 28 rare variants. Of 28 rare variants, 14 with IgAN have genetic changes in the CFHR5 gene and were identified only in patients with IgAN (who exhibited a whether these variants contribute to IgAN susceptibility are total of 22 rare variants), nine were identified only in healthy still unknown. In this study, using a large population of pa- controls (with a total of 23 rare variants), and the other five tients with IgAN, we performed an intensive genetic analysis variants were identified in both patients (23 total rare variants) to explore the genetic effect of variants in the CFHR5 gene on and controls (21 total rare variants). IgAN susceptibility. Because analysis of rare variants requires statistical methods that are fundamentally different than testing commonvariants, we applied Sequence Kernel Association Test (SKAT), which RESULTS can evaluate not only rare variants’ effect but also, the cumu- lative effect of rare and common variants. The results of SKAT Baseline Clinical, Laboratory, and Pathologic showed that the combined effect of rare and common variants Characteristics in CFHR5 had a significant association with IgAN (P=0.03) In total, 1076 individuals were recruited, including 500 patients (Table 2). Furthermore, we investigated common and rare with IgAN (258 men and 242 women) and 576 healthy controls variants separately. Rare variants in CFHR5 presented a sig- (310 men and 266 women). The average ages for patients with nificant association with IgAN (P=0.002) (Table 2), but com- IgAN and controls were 34.23611.09 and 33.5067.66 years mon variants did not (P=0.92) (Table 2). old, respectively. For patients with IgAN, detailed clinical, lab- Regarding the four common variants, we also performed oratory, and pathologic characteristics were also available. single variant–level analysis. In accordance with the results J Am Soc Nephrol 27: 2894–2905, 2016 CFHR5 in IgAN 2895 CLINICAL RESEARCH www.jasn.org c.1513+126A.G in three patients; c.254– 66A.T in two patients; and the following 11 variants, c.-350G.T, c.332A.C, c.430+ 112T.C, c.776T.A, c.790+2T.C, c.790+47A.G, c.1148–121G.A, c.1330+ 78A.G, c.1708T.C, c.1710*3C.G, and c.1710*168G.T, in one patient each).
Load more

Recommended publications
  • Modulation of the Alternative Pathway of Complement by Murine Factor H–Related Proteins
    The Journal of Immunology Modulation of the Alternative Pathway of Complement by Murine Factor H–Related Proteins Alexandra H. Antonioli,* Janice White,† Frances Crawford,† Brandon Renner,* Kevin J. Marchbank,‡ Jonathan P. Hannan,* Joshua M. Thurman,* Philippa Marrack,†,x,{ and V. Michael Holers* Factor H (FH) is a key alternative pathway regulator that controls complement activation both in the fluid phase and on specific cell surfaces, thus allowing the innate immune response to discriminate between self and foreign pathogens. However, the interrela- tionships between FH and a group of closely related molecules, designated the FH-related (FHR) proteins, are currently not well understood. Whereas some studies have suggested that human FHR proteins possess complement regulatory abilities, recent studies have shown that FHR proteins are potent deregulators. Furthermore, the roles of the FHR proteins have not been explored in any in vivo models of inflammatory disease. In this study, we report the cloning and expression of recombinant mouse FH and three FHR proteins (FHR proteins A–C). Results from functional assays show that FHR-A and FHR-B proteins antagonize the protective function of FH in sheep erythrocyte hemolytic assays and increase cell-surface C3b deposition on a mouse kidney proximal tubular cell line (TEC) and a human retinal pigment epithelial cell line (ARPE-19). We also report apparent KD values for the binding interaction of mouse C3d with mouse FH (3.85 mM), FHR-A (136 nM), FHR-B (546 nM), and FHR-C (1.04 mM), which directly correlate with results from functional assays. Collectively, our work suggests that similar to their human counterparts, a subset of mouse FHR proteins have an important modulatory role in complement activation.
    [Show full text]
  • Complement Factor H Deficiency and Endocapillary Glomerulonephritis Due to Paternal Isodisomy and a Novel Factor H Mutation
    Genes and Immunity (2011) 12, 90–99 & 2011 Macmillan Publishers Limited All rights reserved 1466-4879/11 www.nature.com/gene ORIGINAL ARTICLE Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation L Schejbel1, IM Schmidt2, M Kirchhoff3, CB Andersen4, HV Marquart1, P Zipfel5 and P Garred1 1Department of Clinical Immunology, Laboratory of Molecular Medicine, Rigshospitalet, Copenhagen, Denmark; 2Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark; 3Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark; 4Department of Pathology, Rigshospitalet, Copenhagen, Denmark and 5Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany Complement factor H (CFH) is a regulator of the alternative complement activation pathway. Mutations in the CFH gene are associated with atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis type II and C3 glomerulonephritis. Here, we report a 6-month-old CFH-deficient child presenting with endocapillary glomerulonephritis rather than membranoproliferative glomerulonephritis (MPGN) or C3 glomerulonephritis. Sequence analyses showed homozygosity for a novel CFH missense mutation (Pro139Ser) associated with severely decreased CFH plasma concentration (o6%) but normal mRNA splicing and expression. The father was heterozygous carrier of the mutation, but the mother was a non-carrier. Thus, a large deletion in the maternal CFH locus or uniparental isodisomy was suspected. Polymorphic markers across chromosome 1 showed homozygosity for the paternal allele in all markers and a lack of the maternal allele in six informative markers. This combined with a comparative genomic hybridization assay demonstrated paternal isodisomy. Uniparental isodisomy increases the risk of homozygous variations in other genes on the affected chromosome.
    [Show full text]
  • A Novel CFHR5 Mutation Associated with C3 Glomerulonephritis in a Turkish Girl
    A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl Nesrin Besbas, Bora Gulhan, Safak Gucer, Emine Korkmaz & Fatih Ozaltin Journal of Nephrology ISSN 1121-8428 Volume 27 Number 4 J Nephrol (2014) 27:457-460 DOI 10.1007/s40620-013-0008-1 1 23 Your article is protected by copyright and all rights are held exclusively by Italian Society of Nephrology. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy J Nephrol (2014) 27:457–460 DOI 10.1007/s40620-013-0008-1 CASE REPORT A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl Nesrin Besbas • Bora Gulhan • Safak Gucer • Emine Korkmaz • Fatih Ozaltin Received: 17 July 2013 / Accepted: 31 July 2013 / Published online: 5 December 2013 Ó Italian Society of Nephrology 2013 Abstract C3 glomerulopathy defines a subgroup of syndrome and persistently low C3 level, thus expanding the membranoproliferative glomerulonephritis (MPGN) char- genetic and phenotypic spectrum of the disease. Ecu- acterized by complement 3 (C3)-positive, immunoglobu- lizumab seems to be ineffective in this subtype.
    [Show full text]
  • Complement Factor H–Related Hybrid Protein Deregulates Complement in Dense Deposit Disease
    Complement factor H–related hybrid protein deregulates complement in dense deposit disease Qian Chen, … , Christine Skerka, Peter F. Zipfel J Clin Invest. 2014;124(1):145-155. https://doi.org/10.1172/JCI71866. Research Article Nephrology The renal disorder C3 glomerulopathy with dense deposit disease (C3G-DDD) pattern results from complement dysfunction and primarily affects children and young adults. There is no effective treatment, and patients often progress to end-stage renal failure. A small fraction of C3G-DDD cases linked to factor H or C3 gene mutations as well as autoantibodies have been reported. Here, we examined an index family with 2 patients with C3G-DDD and identified a chromosomal deletion in the complement factor H–related (CFHR) gene cluster. This deletion resulted in expression of a hybrid CFHR2-CFHR5 plasma protein. The recombinant hybrid protein stabilized the C3 convertase and reduced factor H–mediated convertase decay. One patient was refractory to plasma replacement and exchange therapy, as evidenced by the hybrid protein quickly returning to pretreatment plasma levels. Subsequently, complement inhibitors were tested on serum from the patient for their ability to block activity of CFHR2-CFHR5. Soluble CR1 restored defective C3 convertase regulation; however, neither eculizumab nor tagged compstatin had any effect. Our findings provide insight into the importance of CFHR proteins for C3 convertase regulation and identify a genetic variation in the CFHR gene cluster that promotes C3G-DDD. Monitoring copy number and sequence variations in the CFHR gene cluster in C3G-DDD and kidney patients with C3G-DDD variations will help guide treatment strategies. Find the latest version: https://jci.me/71866/pdf Research article Complement factor H–related hybrid protein deregulates complement in dense deposit disease Qian Chen,1 Michael Wiesener,2 Hannes U.
    [Show full text]
  • Complement Factor H Related Proteins (Cfhrs)
    G Model MIMM-4208; No. of Pages 11 ARTICLE IN PRESS Molecular Immunology xxx (2013) xxx–xxx Contents lists available at SciVerse ScienceDirect Molecular Immunology jo urnal homepage: www.elsevier.com/locate/molimm Review Complement factor H related proteins (CFHRs) a,∗ a b,c b,d,e Christine Skerka , Qian Chen , Veronique Fremeaux-Bacchi , Lubka T. Roumenina a Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany b Centre de Recherche des Cordeliers, INSERM UMRS 872, Paris, France c Service d’Immunologie Biologique, Hôpital Européen Georges Pompidou, Paris, France d Université Paris Descartes Sorbonne Paris-Cité, Paris, France e Université Pierre et Marie Curie (UPMC-Paris-6), Paris, France a b s t r a c t a r t i c l e i n f o Factor H related proteins comprise a group of five plasma proteins: CFHR1, CFHR2, CFHR3, CFHR4 and Article history: CFHR5, and each member of this group binds to the central complement component C3b. Mutations, Received 1 May 2013 genetic deletions, duplications or rearrangements in the individual CFHR genes are associated with a Accepted 8 May 2013 Available online xxx number of diseases including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathies (C3 glomerulonephritis (C3GN), dense deposit disease (DDD) and CFHR5 nephropathy), IgA nephropathy, age related macular degeneration (AMD) and systemic lupus erythematosus (SLE). Although complement regulatory functions were attributed to most of the members of the CFHR protein family, the precise role of each CFHR protein in complement activation and the exact contribution to disease pathology is still unclear.
    [Show full text]
  • Molecular and Epigenetic Features of Melanomas and Tumor Immune
    Seremet et al. J Transl Med (2016) 14:232 DOI 10.1186/s12967-016-0990-x Journal of Translational Medicine RESEARCH Open Access Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab‑based immunotherapy in metastatic patients Teofila Seremet1,3*† , Alexander Koch2†, Yanina Jansen1, Max Schreuer1, Sofie Wilgenhof1, Véronique Del Marmol3, Danielle Liènard3, Kris Thielemans4, Kelly Schats5, Mark Kockx5, Wim Van Criekinge2, Pierre G. Coulie6, Tim De Meyer2, Nicolas van Baren6,7 and Bart Neyns1 Abstract Background: Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10–15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing indi- vidualized treatment strategies. Methods: Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), whole transcriptome (RNA-seq) and methyl-DNA sequencing (MBD-seq). Results: Patients were divided in two groups according to clinical evolution: durable benefit (DB; 5 patients) and no clinical benefit (NB; 13 patients). 20 metastases were profiled by IHC and 12 were profiled by RNA- and MBD-seq. 325 genes were identified as differentially expressed between DB and NB. Many of these genes reflected a humoral and cellular immune response. MBD-seq revealed differences between DB and NB patients in the methylation of genes linked to nervous system development and neuron differentiation. DB tumors were more infiltrated by CD8+ and PD-L1+ cells than NB tumors.
    [Show full text]
  • Mai Muudatuntuu Ti on Man Mini
    MAIMUUDATUNTUU US009809854B2 TI ON MAN MINI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,809 ,854 B2 Crow et al. (45 ) Date of Patent : Nov . 7 , 2017 Whitehead et al. (2005 ) Variation in tissue - specific gene expression ( 54 ) BIOMARKERS FOR DISEASE ACTIVITY among natural populations. Genome Biology, 6 :R13 . * AND CLINICAL MANIFESTATIONS Villanueva et al. ( 2011 ) Netting Neutrophils Induce Endothelial SYSTEMIC LUPUS ERYTHEMATOSUS Damage , Infiltrate Tissues, and Expose Immunostimulatory Mol ecules in Systemic Lupus Erythematosus . The Journal of Immunol @(71 ) Applicant: NEW YORK SOCIETY FOR THE ogy , 187 : 538 - 552 . * RUPTURED AND CRIPPLED Bijl et al. (2001 ) Fas expression on peripheral blood lymphocytes in MAINTAINING THE HOSPITAL , systemic lupus erythematosus ( SLE ) : relation to lymphocyte acti vation and disease activity . Lupus, 10 :866 - 872 . * New York , NY (US ) Crow et al . (2003 ) Microarray analysis of gene expression in lupus. Arthritis Research and Therapy , 5 :279 - 287 . * @(72 ) Inventors : Mary K . Crow , New York , NY (US ) ; Baechler et al . ( 2003 ) Interferon - inducible gene expression signa Mikhail Olferiev , Mount Kisco , NY ture in peripheral blood cells of patients with severe lupus . PNAS , (US ) 100 ( 5 ) : 2610 - 2615. * GeneCards database entry for IFIT3 ( obtained from < http : / /www . ( 73 ) Assignee : NEW YORK SOCIETY FOR THE genecards. org /cgi - bin / carddisp .pl ? gene = IFIT3 > on May 26 , 2016 , RUPTURED AND CRIPPLED 15 pages ) . * Navarra et al. (2011 ) Efficacy and safety of belimumab in patients MAINTAINING THE HOSPITAL with active systemic lupus erythematosus : a randomised , placebo FOR SPECIAL SURGERY , New controlled , phase 3 trial . The Lancet , 377 :721 - 731. * York , NY (US ) Abramson et al . ( 1983 ) Arthritis Rheum .
    [Show full text]
  • A Genome-Wide Association Study Identifies Key Modulators of Complement Factor H Binding to Malondialdehyde-Epitopes
    A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes Lejla Alica,b,c,1, Nikolina Papac-Milicevica,b,1,2, Darina Czamarad, Ramona B. Rudnicke, Maria Ozsvar-Kozmaa,b, Andrea Hartmanne, Michael Gurbisza, Gregor Hoermanna,f, Stefanie Haslinger-Huttera, Peter F. Zipfele,g, Christine Skerkae, Elisabeth B. Binderd, and Christoph J. Bindera,b,2 aDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria; bResearch Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria; cDepartment of Medical Biochemistry, Faculty of Medicine, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina; dDepartment of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany; eDepartment of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, 07745 Jena, Germany; fCentral Institute for Medical and Chemical Laboratory Diagnosis, University Hospital Innsbruck, 6020 Innsbruck, Austria; and gInstitute for Microbiology, Friedrich Schiller University, 07743 Jena, Germany Edited by Thaddeus Dryja, Harvard Medical School, Boston, MA, and approved March 17, 2020 (received for review August 12, 2019) Genetic variants within complement factor H (CFH), a major head-to-tail fashion. Moreover, its splice variant factor H-like alternative complement pathway regulator, are associated with protein 1 (FHL-1), consisting of the first seven SCRs of CFH, the development of age-related
    [Show full text]
  • FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces
    Published February 26, 2018, doi:10.4049/jimmunol.1701641 The Journal of Immunology FHR5 Binds to Laminins, Uses Separate C3b and Surface-Binding Sites, and Activates Complement on Malondialdehyde-Acetaldehyde Surfaces Ramona B. Rudnick,* Qian Chen,*,1 Emma Diletta Stea,*,2 Andrea Hartmann,* Nikolina Papac-Milicevic,†,‡ Fermin Person,x Michael Wiesener,{ Christoph J. Binder,†,‡ Thorsten Wiech,x Christine Skerka,* and Peter F. Zipfel*,‖ Factor H related-protein 5 (CFHR5) is a surface-acting complement activator and variations in the CFHR5 gene are linked to CFHR glomerulonephritis. In this study, we show that FHR5 binds to laminin-521, the major constituent of the glomerular base- ment membrane, and to mesangial laminin-211. Furthermore, we identify malondialdehyde-acetaldehyde (MAA) epitopes, which are exposed on the surface of human necrotic cells (Homo sapiens), as new FHR5 ligands. Using a set of novel deletion fragments, we show that FHR5 binds to laminin-521, MAA epitopes, heparin, and human necrotic cells (HUVECs) via the middle region [short consensus repeats (SCRs) 5-7]. In contrast, surface-bound FHR5 contacts C3b via the C-terminal region (SCRs8-9). Thus, FHR5 uses separate domains for C3b binding and cell surface interaction. MAA epitopes serve as a complement-activating surface by recruiting FHR5. The complement activator FHR5 and the complement inhibitor factor H both bind to oxidation- specific MAA epitopes and FHR5 competes with factor H for binding. The C3 glomerulopathy–associated FHR21–2-FHR5 hybrid protein is more potent in MAA epitope binding and activation compared with wild-type FHR5. The implications of these results for pathology of CFHR glomerulonephritis are discussed.
    [Show full text]
  • Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
    Published OnlineFirst January 16, 2014; DOI: 10.1158/2159-8290.CD-13-0639 16-CD-13-0639_PAP.indd Page 1 16/01/14 3:10 PM user-f028 ~/Desktop ReseaRch aRticle Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors Jack. F Shern1, Li Chen1, Juliann Chmielecki3,4, Jun S. Wei1, Rajesh Patidar1,a Mar Rosenberg3, Lauren Ambrogio3, Daniel Auclair3, Jianjun Wang1, Young K. Song1, Catherine Tolman1,a Laur Hurd1, Hongling Liao1, Shile Zhang1, Dominik Bogen1, Andrew S. Brohl1, Sivasish Sindiri1, Daniel Catchpoole9, Thomas Badgett1, Gad Getz3, Jaume Mora10, James R. Anderson6, Stephen X. Skapek7, Frederic G. Barr2,w Matthe Meyerson3,4,5, Douglas S. Hawkins8, and Javed Khan1 a bstRact Despite gains in survival, outcomes for patients with metastatic or recurrent rhabdomyosarcoma remain dismal. In a collaboration between the National Cancer Institute, Children’s Oncology Group, and Broad Institute, we performed whole-genome, whole-exome, and transcriptome sequencing to characterize the landscape of somatic alterations in 147 tumor/ normal pairs. Two genotypes are evident in rhabdomyosarcoma tumors: those characterized by the PAX3 or PAX7 fusion and those that lack these fusions but harbor mutations in key signaling pathways. The overall burden of somatic mutations in rhabdomyosarcoma is relatively low, especially in tumors that harbor a PAX3/7 gene fusion. In addition to previously reported mutations in NRAS, KRAS, HRAS, FGFR4, PIK3CA, and CTNNB1, we found novel recurrent mutations in FBXW7 and BCOR, providing potential new avenues for therapeutic intervention. Furthermore, alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed thera- pies that might improve outcomes for patients with rhabdomyosarcoma.
    [Show full text]
  • A Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy
    BRIEF COMMUNICATION www.jasn.org A Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy †‡ Talat H. Malik,* Peter J. Lavin, Elena Goicoechea de Jorge,* Katherine A. Vernon,* | Kirsten L. Rose,* Mitali P. Patel,* Marcel de Leeuw,§ John J. Neary, Peter J. Conlon,¶ † Michelle P. Winn, and Matthew C. Pickering* *Centre for Complement and Inflammation Research, Imperial College, London, United Kingdom; †Department of Medicine, Duke University Medical Center, Durham, North Carolina; ‡Trinity Health Kidney Centre, Tallaght Hospital, Trinity College, Dublin, Ireland; §Beckman Coulter Genomics, Grenoble, France; |Department of Renal Medicine, Royal Infirmary Edinburgh, Edinburgh, United Kingdom; and ¶Department of Nephrology, Beaumont Hospital, Dublin, Ireland ABSTRACT Controlled activation of the complement system, a key component of innate immunity, that CFHR1 and CFHR3 impair comple- enables destruction of pathogens with minimal damage to host tissue. Complement ment processing within the kidney. This factor H (CFH), which inhibits complement activation, and five CFH-related proteins hypothesis would predict that an increase (CFHR1–5) compose a family of structurally related molecules. Combined deletion of in CFHR1 and CFHR3 copy number would CFHR3 and CFHR1 is common and confers a protective effect in IgA nephropathy. Here, enhance susceptibility to complement- we report an autosomal dominant complement-mediated GN associated with abnormal mediated kidney injury. Here, we report increases in copy number across the CFHR3 and CFHR1 loci. In addition to normal a novel CFHR3–1 hybrid gene located on copies of these genes, affected individuals carry a unique hybrid CFHR3–1 gene. an allele that also contained intact copies In addition to identifying an association between these genetic observations and of the CFHR1 and CFHR3 genes.
    [Show full text]
  • The Impact of Complement Genes on the Risk of Late-Onset Alzheimer's
    G C A T T A C G G C A T genes Article The Impact of Complement Genes on the Risk of Late-Onset Alzheimer’s Disease Sarah M. Carpanini 1,2,† , Janet C. Harwood 3,† , Emily Baker 1, Megan Torvell 1,2, The GERAD1 Consortium ‡, Rebecca Sims 3 , Julie Williams 1 and B. Paul Morgan 1,2,* 1 UK Dementia Research Institute at Cardiff University, School of Medicine, Cardiff, CF24 4HQ, UK; [email protected] (S.M.C.); [email protected] (E.B.); [email protected] (M.T.); [email protected] (J.W.) 2 Division of Infection and Immunity, School of Medicine, Systems Immunity Research Institute, Cardiff University, Cardiff, CF14 4XN, UK 3 Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, CF24 4HQ, UK; [email protected] (J.C.H.); [email protected] (R.S.) * Correspondence: [email protected] † These authors contributed equally to this work. ‡ Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for Alzheimer’s disease (GERAD1) Consortium. As such, the investigators within the GERAD1 consortia contributed to the design and implementation of GERAD1 and/or provided data but did not participate in analysis or writing of this report. A full list of GERAD1 investigators and their affiliations is included in Supplementary File S1. Abstract: Late-onset Alzheimer’s disease (LOAD), the most common cause of dementia, and a huge global health challenge, is a neurodegenerative disease of uncertain aetiology. To deliver Citation: Carpanini, S.M.; Harwood, effective diagnostics and therapeutics, understanding the molecular basis of the disease is essential.
    [Show full text]